AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03698825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEW-7197
Description: TEW-7197 50mg tablets + Paclitaxel 80 mg/m2 D1, 8, 15 q 4 weeks TEW-7197 dose will be determined through this dose escalation study
Study NCT04737447 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole Body Vibration Training
Description: Galileo® Trainer is a vibration board. The movement alternating to different sides during walking correlates with the movement on the board due to variable amplitudes and frequencies. Movements of the vibration board are quickly changing and thus simulating the tilting movements of the pelvic during walking but with higher frequency. Muscles of legs and core are activated reflexively. In our study there are performed static practices and pelvic activating practices. Each physiotherapist is experienced in the technical and practical handling of the device.
Study NCT02329834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fursemide Injection Solution for subcutaneous administration (80 mg)
Description: Furosemide Injection Solution, 10mL of undiluted buffered furosemide solution (8mg/mL)
Study NCT02329834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection, USP
Description: Furosemide Injection, USP (10mg/mL), 80 mg by intravenous administration.
Study NCT01915030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein diet
Description: controlled feeding trail. Both arms are caloric restricted
Study NCT01915030 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard protein diet
Study NCT02826629 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Manual dexterity
Description: Control of manual dexterity will be assessed by a force sensor (Power Grip Manipulandum, PGM)
Study NCT02826629 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Oculomotor movements
Description: Oculomotor movements during behavioral task will be recorded using a video-oculography device
Study NCT04462705 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual physiotherapeutic intervention and Abdominal Massage
Description: Abdominal massage is not widely applied amongst general surgery team and is not part of the recommendation. This technique refers to profound manœuvrers of visceras through abdominal palpation and breathing, and has been used as part of the local protocol of Grenoble Alps University Hospital for many years with satisfactory results. No complications have been reported.
Study NCT02826629 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TMS coupled to EMG recording
Description: The involvement of cortical inhibition in this volitional inhibition task will be studied by neuronavigation guided TMS coupled to EMG recording
Study NCT01241032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: 200mg Single Oral Dose of
Study NCT01241032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Udenafil
Description: 200mg Single Oral Dose of
Study NCT02826629 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Psychopathological evaluations
Study NCT01241032 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: Alcohol 39g / 240ml
Study NCT02826629 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological evaluations
Study NCT03600389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Priorities Care
Study NCT04810208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel in NanoZolid formulation, for intratumoural injection
Study NCT06352021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kaleidoscope
Description: The children in the kaleidoscope group were shown the kaleidoscope by the researcher five minutes before the blood sampling, and they were encouraged to look at the kaleidoscope during the procedure and describe the patterns they saw. All children in the Kaleidoscope group agreed to participate in the study. All children in the kaleidoscope group were asked to look at the kaleidoscope just before the tourniquet was placed on their arms before the blood sampling procedure and to describe the patterns, they saw in it by turning it slowly during the procedure.
Study NCT01982682 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation (TBI)
Description: Undergo TBI
Study NCT01982682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion (DLI)
Description: Undergo DLI
Study NCT01982682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01982682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (HSCT)
Description: Undergo CD34+ selected allogeneic HSCT
Study NCT01982682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Given IV
Study NCT01069965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGP-15 100 mg QD
Description: Two 50 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
Study NCT01069965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGP-15 100 mg BID
Description: One 100 mg BGP-15 capsule by mouth in the morning; and one 100 mg BGP-15 capsule by mouth in the evening
Study NCT01069965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo BID
Description: Two Placebo capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
Study NCT01069965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGP-15 200 mg QD
Description: Two 100 mg BGP-15 capsule by mouth in the morning; and two Placebo capsule by mouth in the evening
Study NCT02928289 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VISCO360 ab interno canaloplasty surgery
Description: 360 degrees of viscodilation of Schlemm's canal
Study NCT02928289 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Laser Trabeculoplasty (SLT)
Description: 360 degrees of selective laser trabeculoplasty
Study NCT00695344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus 2 times per day, v.o., 2 years treatment.
Study NCT00695344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azathioprine or mycophenolate mofetil
Description: 2 times per day during 2 years
Study NCT04240392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC)
Description: The sites randomized to CC will have 4-6 on-site support visits at the outset of the study. These visits will occur during the first 3 months of the project. During these visits, study staff will again review buprenorphine induction procedures (heretofore referred to as initiation rather than induction) and dosing of buprenorphine as well as therapeutic behavioral treatments. The investigators will provide the center with forms and educational materials as well as an app that can be run to help dosing during initiation procedures. At the same time, the investigators will teach obstetricians, nurses and support staff the principles of motivational interviewing. The investigators will set up visits for the CM to meet with a recovery coach trainer provided by the investigators' community partner.
Study NCT04240392 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Extension for Community Healthcare Outcomes (ECHO)
Description: The Weitzman Institute (WI), a community partner and provider for the ECHO condition, is a research and innovation center focused on improving care for medically underserved and special populations. Since 2013, CHCI/WI has provided education and technical assistance through an established video conference and online learning platforms to over 800 primary care providers and over 200 care team members who treat patients with chronic pain and opioid addiction. WI partners with national experts in pain care, substance abuse disorder, and MAT to create and deliver a robust training program for clinicians across the country through Project ECHO ®. The WI will work with the study team to develop and staff the sessions.
Study NCT03469232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huanglian-Jiedu Decoction
Description: Huanglian-Jiedu Decoction includes 4 kinds of Chinese herbs as following: Huanglian (Rhizoma Coptidis), Huangbo (Cortex Phellodendri), Huangqin (Scutellaria baicalensis) and Zhizi (Scutellaria baicalensis). All of them were prepared as granule.
Study NCT03207984 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root coverage surgery
Description: Periodontal plastic surgery aiming the treatment of multiple gingival recessions in aesthetics areas with SCTG and CM
Study NCT03207984 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root coverage surgery
Description: Periodontal plastic surgery aiming the treatment of multiple gingival recessions in aesthetics areas with SCTG and CM
Study NCT00592306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thymoglobulin (intraoperative)
Description: All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.~Each arm will also receive a single placebo dose.~Arm I will receive thymoglobulin intraoperatively followed by a postoperative placebo dose and two subsequent thymoglobulin doses.
Study NCT00592306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: thymoglobulin (postoperative)
Description: All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.~Each arm will also receive a single placebo dose.~Arm II will receive placebo intraoperatively followed by 3 postoperative doses of thymoglobulin.
Study NCT00245518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflavone
Study NCT01069965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGP-15 200 mg BID
Description: Two 100 mg BGP-15 capsules by mouth in the morning; and two 100 mg BGP-15 capsules by mouth in the evening
Study NCT01069965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGP-15 400 mg QD
Description: Two 200 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
Study NCT05301010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faceptor
Description: NNG-TMAB (trastuzumab) 150 mg, 440 mg, lyophilized power for injection, manufacturered by Nanogen Pharmaceutical Biotechnology JSC.
Study NCT05301010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: Herceptin (trastuzumab) 150mg, 440mg, powder for concentrate for solution, manufactured by Roche.
Study NCT05301010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: The drug Docetaxel in this study has the brand name Taxotere manufactured by Sanofi company.
Study NCT05301010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: The drug Docetaxel in this study has the brand name Taxotere manufactured by Sanofi company.
Study NCT01403493 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Study NCT01340053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX5791
Description: Capsule, QD
Study NCT01340053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RDX5791
Description: Capsule, QD
Study NCT05028335 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Carbamide Peroxide (PC) 22%) + placebo gel
Description: Application of one drop of Polanight bleaching agent (SDI, SP, Brazil) on each corresponding tooth in a tray that was used for 45 minutes a day, for a period of twenty-one days. After the bleaching treatment, the participants were instructed to wash the trays under running water and dry them. The volunteers were instructed to apply a small amount of placebo gel, without active ingredient, with color, texture and odor similar to 1.5% oxalate gel (Painless, BM4, SC, Brazil) in the spaces related to the vestibular portions of the teeth trays, which were used for 10 minutes.
Study NCT05028335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbamide Peroxide (PC) 22%) + Potassium Oxalate gel 1.5%
Description: Application of one drop of Polanight bleaching agent (SDI, SP, Brazil) on each corresponding tooth in a tray that was used for 45 minutes a day, for a period of twenty-one days. After the bleaching treatment, the participants were instructed to wash the trays under running water and dry them with absorbent paper. The volunteers applied a small amount of 1.5% potassium oxalate gel (Painless, BM4, SC, Brazil) in the spaces relative to the vestibular portions of the tray's teeth, which were used for 10 minutes.
Study NCT00955539 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AV-optimization followed by AV- and VV-optimization
Description: Patients are AV-optimized the first 4 months,then AV- and VV-optimized the next 4 months.
Study NCT00955539 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AV- and VV-optimization followed by AV-optimization only.
Description: Patients are AV- and VV-optimized the first 4 months,then AV-optimized the next 4 months.
Study NCT04264156 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lucinactant for Inhalation
Description: A drug-device combination product that delivers aerosolized SRT to preterm neonates with RDS who are being supported with nasal continuous positive airway pressure (nCPAP).
Study NCT04264156 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: nCPAP Only
Description: Nasal continuous positive airway pressure (nCPAP) alone
Study NCT04706442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Parenting Application
Description: The Supportive Parenting Application is a theory-based perinatal educational intervention for couples administered through a mobile application. The mobile app consist of knowledge-based content, informational videos and audio, discussion forum, chat groups with peer volunteers, and an experts advice section
Study NCT04234841 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Blood test
Study NCT02700893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atropine+ propofol
Description: Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants \< 1000g - Renewable once 2.5 mg/kg for infants > 1000G - Possible additional dose of 1 mg/kg
Study NCT02700893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atropine + atracurium + sufentanil
Description: Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants \< 1000g 0.2 µg/kg for infants > 1000g
Study NCT02415907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [ethyl-1-14C]-idalopirdine
Description: 120 mg/2.40 MBq Lu AF67708 (\[ethyl-1-14C\]-idalopirdine) in one capsule for oral administration, single dose
Study NCT02415907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [benzyl-7-14C]-idalopirdine
Description: 120 mg/2.40 MBq Lu AF67709 (\[benzyl-7-14C\]-idalopirdine) in one capsule for oral administration, single dose
Study NCT03315780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC
Study NCT03315780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC
Study NCT04106674 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction internal stabilisation (ORIF)
Description: Treatment allocated to surgical or non-surgical group. Implant choice pragmatic, surgeons choice.
Study NCT04462705 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual physiotherapeutic intervention and Abdominal Massage
Description: Abdominal massage is not widely applied amongst general surgery team and is not part of the recommendation. This technique refers to profound manœuvrers of visceras through abdominal palpation and breathing, and has been used as part of the local protocol of Grenoble Alps University Hospital for many years with satisfactory results. No complications have been reported.
Study NCT04036656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA136 0.5 mg
Description: oral tablet
Study NCT04036656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA136 1 mg
Description: oral tablet
Study NCT01716546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Study NCT03358017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronate
Description: 4 mg i.v. every 3/4 weeks for 6 months
Study NCT03610191 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum biomarker tests
Description: Blood was collected at preoperatively, immediately after operation and 24 h after operation in patients from the surgical group but not volunteers. Serum MD2, CysC, DNA methylation marker and SNP mutation sites on CTNNA2 gene were test.
Study NCT03610191 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neuropsychological battery tests
Description: both surgical patients and volunteers will accept three times of NPB tests. For surgical patients the tested time point are preoperative, one day before discharge and 3 months after surgery. For volunteers the tested time interval would be similar to that of surgical patients.
Study NCT03610191 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: patients scheduled for cardiac surgery will accept the surgical procedure.
Study NCT02134444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Experimental group will receive a game-based exercise program delivered at home. This includes provision of a head-mounted motion mouse. This provides a treatment tool applied to gaze control, and allows incorporation of balance exercises. It also allows many different therapeutic exercises to be coupled to a wide range of inexpensive commercial computer games. Participants will attend 3 clinical sessions during which time the home therapy programs will be established and training in the use of the motion mouse and games will be provided. The treating physiotherapist will attend the participant's home to ensure proper set-up and operation of the computer applications. Participants will be asked to perform their respective home programs four times per week for 20 minutes per session.
Study NCT02134444 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Control group will receive a vestibular exercise program which will include the Herdman gaze stabilization exercises and balance training program. This program is presently a standard of vestibular care. Participants will attend an out-patient physical therapy clinic once a week for 12 weeks. The program also includes a 20 minute home exercise program prescribed 4 times per week.
Study NCT00226486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multifactorial intervention
Description: Identification of medical, cardiovascular, physical risk factors for falls; e.g. vision, drug-use, depression, carotid sinus syndrome, orthostatic hypotension, etc. Individual intervention; treatment of disease, drug review, pacemaker, exercises, new glasses, all if indicated.
Study NCT00226486 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: No intervention, but ususal care after an accidental fall.
Study NCT03971565 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample 5 milliliter
Description: The blood of the patients will be collected during their hospitalization of the hematology department participating in the research
Study NCT00695526 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cranberry
Description: cranberry extractive in powder product (by Triarco Industries, Inc. NJ, USA) and encapsulated in dose of 500mg/capsule (by Topo digital tech co., Taiwan). By one capsule after each of three meals per day.
Study NCT00726635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive intervention
Description: The intervention will last one hour and will include cognitive technique (self-talk). The technique will be demonstrated to the woman, practiced with her, and taped so as to encourage further practice at home.
Study NCT00726635 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: A one hour conversation with a nurse
Study NCT00726635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psycho-physiological intervention
Description: The intervention will last an hour and will include a psycho-physiological intervention (relaxation and guided imagery). The technique will be demonstrated to the woman, practiced with her, and taped so as to assure further practice at home
Study NCT03491514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Granola
Description: 51 g Test Granola
Study NCT03491514 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Granola
Description: 54.1 Control Granola
Study NCT03358017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg
Description: 80mg /die os for 6 months
Study NCT00406276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 will be given at a dose of 5mg/day in combination with docetaxel
Study NCT00406276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: In combination with RAD001
Study NCT00940901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: sildenafil 50 mg tablet daily for first 8 weeks (phase 1), and then sildenafil 50 mg tablet daily for final 8 weeks (phase 2)